Abstract
Phosphate binders and dialysis can have harmful side-effects during the treatments of hyperphosphatemia. Therefore, we evaluated the capability of intestinal bacteria (lactic acid bacteria and bifidobacteria) as phosphate-accumulating organisms (PAOs) for phosphate accumulation, with the aim of determining whether PAO-formulated food can prevent hyperphosphatemia in the early stages. However, methods for estimating microbial phosphate-accumulation capacities require significant improvements regarding specificity, cost, and simplicity. The presented method analyzed cell-free broth to assess the phosphate accumulation capability of cells. Active cells and the constructed phosphate-deficient cells were incubated in assay salt media. After incubation, phosphate-deficient cell-free broth was taken as sample and the blank was the active cell-free broth. Therefore, effects of interfering agents and other metabolites were avoided and enhanced the specificity remarkably. Phosphate contents were assessed by reactions with toluidine blue O. In contrast to the case in previous studies, the shift in the first absorbance peak was found to be inversely proportional to the phosphate concentration. The minimum detectable phosphate concentrations for the 11th isolate of Lactobacillus casei JCM 1134 and 8th isolate of Bifidobacterium adolescentis JCM 1275 were determined to be 1.24 and 0.4 mg/L, respectively. Further, the validation results were found to be significant (p-value < 0.05).
Highlights
Phosphate binders and dialysis can have harmful side-effects during the treatments of hyperphosphatemia
Current popular treatments for chronic kidney disease (CKD)-linked hyperphosphatemia include reducing the dietary intake of phosphorus, phosphate-binding chemotherapy, and the removal of phosphorus by dialysis
If intestinal bacteria were found to exhibit good phosphate-removing properties, they could potentially be used for preventing hyperphosphatemia in the initial stages of CKD, as it is known that care is better than cure
Summary
Phosphate binders and dialysis can have harmful side-effects during the treatments of hyperphosphatemia. Current popular treatments for CKD-linked hyperphosphatemia include reducing the dietary intake of phosphorus, phosphate-binding chemotherapy, and the removal of phosphorus by dialysis. These affect the quality of life as they can result in heavy metal deposition, involve strict dialysis schedules, and can lead to hypercalcemia and other metabolic anomalies[2]. Phosphate-removing probiotics may offer a safer and healthier prevention strategy owing to their associated gut-health benefits, which help maintain the quality of life. The American Public Health Association proposed three standard digestion methods[3] for determining the phosphate content These include using perchloric acid, using nitric–sulfuric acid, and persulfate oxidation. With respect to wastewater research, the persulfate oxidation method[4] is the simplest and most rapid approach (the treatment time is approximately 2 h)[5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
